The US Food and Drug Administration (FDA) has reached an agreement with Omeros on the protocol for its Phase lll clinical trial to assess OMS721 in patients with IgA nephropathy (IgAN).

The randomised, double-blind, placebo-controlled trial will be conducted in patients who are at least 18 years of age with biopsy-confirmed IgAN and with 24hr urine protein excretion greater than 1g/day at baseline on optimised renin-angiotensin system (RAS) blockade.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Omeros chairman and CEO Gregory Demopulos said: “Final preparations to begin the trial can now be completed and enrolment is expected to open in early February.

“To our OMS721 Phase lll programmes in IgA nephropathy and atypical hemolytic uremic syndrome (aHUS), we have recently added a third Phase lll programme in stem cell transplant-associated TMA.”

“Final preparations to begin the trial can now be completed and enrolment is expected to open in early February.”

During the upcoming Phase lll trial, patients will be given an initial 12 weekly intravenous doses of study drug, as well as additional weekly dosing for partial responders and relapsers.

The trial’s primary endpoint is to reduce the level of proteinuria at 24 weeks after dosing starts.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial intends to use an adaptive design that will allow intra-trial adjustment in a sample size. In order to perform safety and efficacy assessments, the initial sample size for the proteinuria endpoint is estimated at 140 patients in each of the treatment and placebo groups.

It will result in adding a subset of patients with high levels of proteinuria at baseline, and full approval could also be obtained if a substantial improvement is seen at 24 weeks in this subset of patients alone.